KRAS and neoplasm: The tumor-specificity and therapeutic potential of the selected TCRs are reinforced by functional characterization of the TCR-T cells, the gene expression signatures of the original TIL clonotypes, the fact, that the clonotypes were found infiltrating a tumor relapse acquired more than 30 months after surgery of the primary tumor, and the discovery of highly homologous to identical TCRs in six of 29 archival (FFPE) tumor samples with confirmed KRAS Q61H-mutation.